Lancet:早期进食方式对重症患者预后的影响

2017-11-09 zhangfan MedSci原创

研究认为,对于危重休克患者,与早期肠外营养相比,肠内营养补充不能降低死亡率或继发感染的风险,反而会增加更大的消化并发症风险

近日研究人员考察了早期进食方式对危重患者预后的影响。

NUTRIREA-2研究在法国44个重症监护中心开展,接受有创机械通气和升压治疗的休克患者参与。患者随机在插管后24小时进行肠外或肠内营养补充,目标剂量为20-25 kcal/kg/d。研究的主要终点是28天内死亡率。

研究在第二次中期分析后终止,总计2410名患者参与,其中肠内营养组1202人,肠外营养组1208人。28天后,443名 (37%)肠内营养组和422名(35%)肠外营养组患者死亡,差异为2%。组间ICU获得性感染的累积发病率无显著差异(14% vs 16%)。相比于肠外营养组,肠内营养组患者呕吐(406 例[34%] vs 246例 [20%]; HR 1.89 [1.62-2.20])、腹泻(432例[36%] vs 393例[33%]; 1.20 [1.05-1.37])、肠道缺血 (19例 [2%] vs5例[<1%]; 3.84 [1.43-10.3])以及急性假性结肠梗阻(11例 [1%] vs3例[<1%]; 3.7 [1.03-13.2)的累积发病率更高。

研究认为,对于危重休克患者,与早期肠外营养相比,肠内营养补充不能降低死亡率或继发感染的风险,反而会增加更大的消化并发症风险。

原始出处:


本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (6)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1691938, encodeId=1de1169193832, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Dec 13 14:59:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829316, encodeId=996a1829316fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 09 22:59:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262624, encodeId=62cb26262456, content=同国内的研究结果不一致呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJNCjP5GJqqBZFlbk1Dm8cXyP7gpY57Ut698B6phuTyicrxr4kcWYkhhCCeAmco6PFOMa0JSribUP9A/0, createdBy=cfcb2174142, createdName=wangvase, createdTime=Sun Nov 19 20:23:04 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284017, encodeId=497a128401e14, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585122, encodeId=e9461585122c7, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260036, encodeId=1aad260036ed, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Nov 09 18:33:09 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1691938, encodeId=1de1169193832, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Dec 13 14:59:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829316, encodeId=996a1829316fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 09 22:59:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262624, encodeId=62cb26262456, content=同国内的研究结果不一致呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJNCjP5GJqqBZFlbk1Dm8cXyP7gpY57Ut698B6phuTyicrxr4kcWYkhhCCeAmco6PFOMa0JSribUP9A/0, createdBy=cfcb2174142, createdName=wangvase, createdTime=Sun Nov 19 20:23:04 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284017, encodeId=497a128401e14, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585122, encodeId=e9461585122c7, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260036, encodeId=1aad260036ed, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Nov 09 18:33:09 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2018-02-09 howi
  3. [GetPortalCommentsPageByObjectIdResponse(id=1691938, encodeId=1de1169193832, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Dec 13 14:59:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829316, encodeId=996a1829316fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 09 22:59:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262624, encodeId=62cb26262456, content=同国内的研究结果不一致呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJNCjP5GJqqBZFlbk1Dm8cXyP7gpY57Ut698B6phuTyicrxr4kcWYkhhCCeAmco6PFOMa0JSribUP9A/0, createdBy=cfcb2174142, createdName=wangvase, createdTime=Sun Nov 19 20:23:04 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284017, encodeId=497a128401e14, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585122, encodeId=e9461585122c7, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260036, encodeId=1aad260036ed, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Nov 09 18:33:09 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2017-11-19 wangvase

    同国内的研究结果不一致呢

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1691938, encodeId=1de1169193832, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Dec 13 14:59:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829316, encodeId=996a1829316fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 09 22:59:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262624, encodeId=62cb26262456, content=同国内的研究结果不一致呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJNCjP5GJqqBZFlbk1Dm8cXyP7gpY57Ut698B6phuTyicrxr4kcWYkhhCCeAmco6PFOMa0JSribUP9A/0, createdBy=cfcb2174142, createdName=wangvase, createdTime=Sun Nov 19 20:23:04 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284017, encodeId=497a128401e14, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585122, encodeId=e9461585122c7, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260036, encodeId=1aad260036ed, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Nov 09 18:33:09 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1691938, encodeId=1de1169193832, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Dec 13 14:59:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829316, encodeId=996a1829316fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 09 22:59:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262624, encodeId=62cb26262456, content=同国内的研究结果不一致呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJNCjP5GJqqBZFlbk1Dm8cXyP7gpY57Ut698B6phuTyicrxr4kcWYkhhCCeAmco6PFOMa0JSribUP9A/0, createdBy=cfcb2174142, createdName=wangvase, createdTime=Sun Nov 19 20:23:04 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284017, encodeId=497a128401e14, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585122, encodeId=e9461585122c7, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260036, encodeId=1aad260036ed, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Nov 09 18:33:09 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2017-11-11 gj0737
  6. [GetPortalCommentsPageByObjectIdResponse(id=1691938, encodeId=1de1169193832, content=<a href='/topic/show?id=a450530853c' target=_blank style='color:#2F92EE;'>#患者预后#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=53085, encryptionId=a450530853c, topicName=患者预后)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=8f4729287700, createdName=bnurmamat, createdTime=Wed Dec 13 14:59:00 CST 2017, time=2017-12-13, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1829316, encodeId=996a1829316fe, content=<a href='/topic/show?id=1b6210686b2' target=_blank style='color:#2F92EE;'>#Lancet#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=24, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=10686, encryptionId=1b6210686b2, topicName=Lancet)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=3f0227, createdName=howi, createdTime=Fri Feb 09 22:59:00 CST 2018, time=2018-02-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=262624, encodeId=62cb26262456, content=同国内的研究结果不一致呢, beContent=null, objectType=article, channel=null, level=null, likeNumber=49, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/vi_32/Q0j4TwGTfTJNCjP5GJqqBZFlbk1Dm8cXyP7gpY57Ut698B6phuTyicrxr4kcWYkhhCCeAmco6PFOMa0JSribUP9A/0, createdBy=cfcb2174142, createdName=wangvase, createdTime=Sun Nov 19 20:23:04 CST 2017, time=2017-11-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284017, encodeId=497a128401e14, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=31, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1585122, encodeId=e9461585122c7, content=<a href='/topic/show?id=625c9440e39' target=_blank style='color:#2F92EE;'>#进食#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=94407, encryptionId=625c9440e39, topicName=进食)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=94cc17130334, createdName=gj0737, createdTime=Sat Nov 11 01:59:00 CST 2017, time=2017-11-11, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=260036, encodeId=1aad260036ed, content=学习学习.了解了解, beContent=null, objectType=article, channel=null, level=null, likeNumber=48, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=93f31631454, createdName=1dd8c52fm63(暂无匿称), createdTime=Thu Nov 09 18:33:09 CST 2017, time=2017-11-09, status=1, ipAttribution=)]
    2017-11-09 1dd8c52fm63(暂无匿称)

    学习学习.了解了解

    0

相关资讯

NEJM:早期雌激素受体阳性乳腺癌患者内分泌治疗后5-20年复发风险及影响因素研究

研究认为,对于早期雌激素受体阳性乳腺癌患者,在接受了5年的内分泌治疗后,其5-20年的疾病复发风险保持稳定。远端复发风险与患者初始淋巴结受累密切相关,其复发风险为10-41%,主要与患者的TN状态与肿瘤分级有关

Oncotarget:小身材的大作用——miR-148/miR-152家族的预后价值

本期为大家介绍一篇基于观察研究的系统回顾来评估miR-148/miR-152家族在癌症患者中预后价值的文章。文章发表在Oncotarget期刊上,题目为Evaluatingthe prognostic value of miR-148/152 family in cancers: based on a systemicreview of observational studies(基于观察研究的系

Cancer Res:糖尿病治疗与早期乳腺癌患者不良乳腺癌预后风险之间的关系

很多研究报道糖尿病药物二甲双胍可以降低乳腺癌发病率,但是其是否会影响乳腺癌确诊后病情进展上未知。Cancer Res近期发表了一批文章,对SEER数据库数据进行回顾性分析,研究二甲双胍对早期乳腺癌患者预后的影响。

ANN ONCOL:反应程度与接受靶向或免疫治疗的转移性非小细胞肺癌患者预后的关系

实体瘤反应评价标准(RECIST)可以对肿瘤新治疗策略疗效进行快速评估。但是RECIST不能反应疗效良好的治疗反应异质性。肿瘤反应程度可能为治疗反应提供更详细的认识。ANN ONCOL近期发表了一篇文章,研究接受ALK抑制剂(ALKi)或抗PD-1抗体治疗的非小细胞肺癌患者反应程度(DepOR)与总生存和无进展生存之间的关系。

ANN ONCOL:MAPK信号通路基因改变对接受一线FOLFIRI联合贝伐单抗治疗的转移性结直肠癌患者预后的影响

MAPK酶1(MKNK1)位于RAS/RAF/ERK和MAP3K1/MKK/p38信号通路的下游。磷酸化MKNK1调节翻译起始因子4E的功能。翻译起始因子4E是转录控制的关键因素,其表达在转移性结直肠癌患者中升高。临床前数据表明MKNK1上调血管生成因子促进血管生成。ANN ONCOL近期发表了一篇文章,研究MKNK1基因改变是否可以预测接受一线FOLFIRI和贝伐单抗治疗的转移性结直肠癌患者的预

SCI REP:术前B型钠尿肽前体N末端浓度和脑肿瘤患者的预后相关性分析!

总之,术前NT-proBNP浓度升高与脑肿瘤患者健康状况恶化、不良结局及生存期缩短有关。